Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/72272
Título: KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
Autores/as: Gadgeel, S.
Rodríguez Abreu, Delvys 
Felip, E.
Esteban, E.
Speranza, G.
Reck, M.
Hui, R.
Boyer, M.
Garon, E. B.
Horinouchi, H.
Cristescu, R.
Aurora-Garg, D.
Lunceford, J.
Kobie, J.
Ayers, M.
Piperdi, B.
Pietanza, M. C.
Garassino, M. C.
Clasificación UNESCO: 320101 Oncología
320508 Enfermedades pulmonares
Fecha de publicación: 2019
Publicación seriada: Annals of Oncology 
Conferencia: Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO) 
Resumen: Background : KRAS mutations are observed in ∼25% of lung adenocarcinomas, with some studies suggesting it is a prognostic factor in NSCLC. We assessed the prevalence of KRAS mutations and their association with efficacy in an exploratory analysis of the KEYNOTE-189 study of pembrolizumab plus pemetrexed and platinum chemotherapy vs placebo plus chemotherapy as first-line therapy for metastatic non-squamous NSCLC (NCT02578680). Methods: Whole-exome sequencing (WES) was used to assess KRAS status and tumor mutational burden (TMB) in participants (pts) who had available tumor and matched-normal tissue. Descriptive analyses of the association of KRAS and KRAS G12C status with efficacy were included as part of this exploratory analysis, as was correlation between KRAS mutational status and shifts in TMB and PD-L1 expression distributions. Results: 289 (47%) of 616 pts had evaluable WES data from both tumor and normal DNA. 89 (31%) of 289 pts had KRAS mutation, including 37 (13%) G12C carriers. Pts with vs without KRAS mutations tended to have higher PD-L1 TPS (median [IQR] 30% [1-71] vs 5% [0-60]) and higher TMB (median [IQR] 204 [137-276] vs 141 [85-252] mut/exome). Outcomes of pembrolizumab plus chemotherapy and of placebo plus chemotherapy in pts with and without KRAS mutation and in KRAS G12C carriers are summarized in the table. 95% CIs were wide given the modest frequency of KRAS mutation, particularly KRAS G12C, and the 2:1 randomization that resulted in small populations for placebo plus chemotherapy.
URI: http://hdl.handle.net/10553/72272
ISSN: 0923-7534
Fuente: Annals Of Oncology [ISSN 0923-7534], v. 30 sup. 11, p. 64-65, Abstract LBA5, (Diciembre 2019)
Colección:Actas de congresos
Vista completa

Citas de WEB OF SCIENCETM
Citations

44
actualizado el 25-feb-2024

Visitas

100
actualizado el 03-mar-2024

Google ScholarTM

Verifica


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.